AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

Lumos isn't bogged down by slow-moving gantry heads. Instead, it's built around a Galvo system —the same kind used in high-speed industrial lasers, where mirrors redirect the beam at blinding ...

As of June 27, 2025, Recursion Pharmaceuticals, Inc. had a $2.0 billion market cap, putting it in the 58th percentile of all stocks. Recursion Pharmaceuticals, Inc.’s stock is down 25.6% in 2025, NA 0 ...

OxyContin maker Purdue Pharma ’s latest plan to settle thousands of lawsuits over the toll of opioids could soon move forward after every U.S. state involved agreed to it.

Stockhead’s Tylah Tully unpacks the latest from Lumos Diagnostics (ASX:LDX), who have enrolled its 500th patient in a CLIA waiver study for FebriDx, its rapid point-of-care diagnostic test to ...

About TME Pharma TME Pharma is a clinical-stage company focused on developing novel therapies for treatment of the most aggressive cancers. The company’s oncology-focused pipeline is designed to act ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company and the Singapore Eye Research Institute (SERI), a leading ophthalmology research institution, today ...

Taking advantage of a broken patent system, Big Pharma is making minor tweaks to medications just to keep affordable generics off the market, a new report suggests. They’ve made billions of dollars in ...

The state of Maine is expected to receive $26 million from Purdue Pharma and its owners, the Sackler family, as part of the $7.4 billion settlement that will resolve lawsuits over the company's ...

Under the terms of the agreement, Supernus will commence a tender offer to acquire all outstanding shares of Sage Therapeutics, Inc. for a purchase price of $8.50 per share in cash (or an aggregate of ...